These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 22320327

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives.
    Norman MH, Liu L, Lee M, Xi N, Fellows I, D'Angelo ND, Dominguez C, Rex K, Bellon SF, Kim TS, Dussault I.
    J Med Chem; 2012 Mar 08; 55(5):1858-67. PubMed ID: 22320343
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.
    Schroeder GM, An Y, Cai ZW, Chen XT, Clark C, Cornelius LA, Dai J, Gullo-Brown J, Gupta A, Henley B, Hunt JT, Jeyaseelan R, Kamath A, Kim K, Lippy J, Lombardo LJ, Manne V, Oppenheimer S, Sack JS, Schmidt RJ, Shen G, Stefanski K, Tokarski JS, Trainor GL, Wautlet BS, Wei D, Williams DK, Zhang Y, Zhang Y, Fargnoli J, Borzilleri RM.
    J Med Chem; 2009 Mar 12; 52(5):1251-4. PubMed ID: 19260711
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
    Williams DK, Chen XT, Tarby C, Kaltenbach R, Cai ZW, Tokarski JS, An Y, Sack JS, Wautlet B, Gullo-Brown J, Henley BJ, Jeyaseelan R, Kellar K, Manne V, Trainor GL, Lombardo LJ, Fargnoli J, Borzilleri RM.
    Bioorg Med Chem Lett; 2010 May 01; 20(9):2998-3002. PubMed ID: 20382527
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
    Kuo GH, Prouty C, Wang A, Emanuel S, Deangelis A, Zhang Y, Song F, Beall L, Connolly PJ, Karnachi P, Chen X, Gruninger RH, Sechler J, Fuentes-Pesquera A, Middleton SA, Jolliffe L, Murray WV.
    J Med Chem; 2005 Jul 28; 48(15):4892-909. PubMed ID: 16033269
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis and evaluation of highly selective pyridone-based class II MET inhibitors.
    She N, Zhuo L, Jiang W, Zhu X, Wang J, Ming Z, Zhao X, Cong X, Huang W.
    Bioorg Med Chem Lett; 2014 Aug 01; 24(15):3351-5. PubMed ID: 24951334
    [Abstract] [Full Text] [Related]

  • 9. Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities.
    Kim KS, Zhang L, Schmidt R, Cai ZW, Wei D, Williams DK, Lombardo LJ, Trainor GL, Xie D, Zhang Y, An Y, Sack JS, Tokarski JS, Darienzo C, Kamath A, Marathe P, Zhang Y, Lippy J, Jeyaseelan R, Wautlet B, Henley B, Gullo-Brown J, Manne V, Hunt JT, Fargnoli J, Borzilleri RM.
    J Med Chem; 2008 Sep 11; 51(17):5330-41. PubMed ID: 18690676
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
    Wang Y, Ai J, Wang Y, Chen Y, Wang L, Liu G, Geng M, Zhang A.
    J Med Chem; 2011 Apr 14; 54(7):2127-42. PubMed ID: 21405128
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.
    Bode CM, Boezio AA, Albrecht BK, Bellon SF, Berry L, Broome MA, Choquette D, Dussault I, Lewis RT, Lin MH, Rex K, Whittington DA, Yang Y, Harmange JC.
    Bioorg Med Chem Lett; 2012 Jun 15; 22(12):4089-93. PubMed ID: 22595176
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Structure-guided identification of novel VEGFR-2 kinase inhibitors via solution phase parallel synthesis.
    Tripathy R, Reiboldt A, Messina PA, Iqbal M, Singh J, Bacon ER, Angeles TS, Yang SX, Albom MS, Robinson C, Chang H, Ruggeri BA, Mallamo JP.
    Bioorg Med Chem Lett; 2006 Apr 15; 16(8):2158-62. PubMed ID: 16460933
    [Abstract] [Full Text] [Related]

  • 18. Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase.
    Prime ME, Courtney SM, Brookfield FA, Marston RW, Walker V, Warne J, Boyd AE, Kairies NA, von der Saal W, Limberg A, Georges G, Engh RA, Goller B, Rueger P, Rueth M.
    J Med Chem; 2011 Jan 13; 54(1):312-9. PubMed ID: 21128645
    [Abstract] [Full Text] [Related]

  • 19. Identification of inhibitors of protein kinase B using fragment-based lead discovery.
    Saxty G, Woodhead SJ, Berdini V, Davies TG, Verdonk ML, Wyatt PG, Boyle RG, Barford D, Downham R, Garrett MD, Carr RA.
    J Med Chem; 2007 May 17; 50(10):2293-6. PubMed ID: 17451234
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.